

CITATION REPORT

List of articles citing

Monoclonal Antibody Biosimilars in Oncology: Critical Appraisal of Available Data on Switching

DOI: 10.1016/j.clinthera.2018.03.018
Clinical Therapeutics, 2018, 40, 798-809.e2.

Source: <https://exaly.com/paper-pdf/69308094/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
19	Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars. <i>Pharmaceutics</i> , 2018 , 10,	6.4	8
18	The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars. <i>British Journal of Cancer</i> , 2019 , 121, 199-210	8.7	31
17	Are Biosimilars the Future of Oncology and Haematology?. <i>Drugs</i> , 2019 , 79, 1609-1624	12.1	3
16	Drug Discontinuation in Studies Including a Switch From an Originator to a Biosimilar Monoclonal Antibody: A Systematic Literature Review. <i>Clinical Therapeutics</i> , 2019 , 41, 155-173.e13	3.5	16
15	Demystifying biosimilars: development, regulation and clinical use. <i>Future Oncology</i> , 2019 , 15, 777-790	3.6	13
14	Comparative immunogenicity assessment of biosimilars. <i>Future Oncology</i> , 2019 , 15, 319-329	3.6	10
13	Rituximab biosimilars in hematologic malignancies: the need for a real-world approach. <i>Future Oncology</i> , 2020 , 16, 2017-2027	3.6	4
12	The Efficacy, Safety, and Immunogenicity of Switching Between Reference Biopharmaceuticals and Biosimilars: A Systematic Review. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 734-755	6.1	45
11	Enhancing global access to cancer medicines. <i>Ca-A Cancer Journal for Clinicians</i> , 2020 , 70, 105-124	220.7	63
10	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 ,	2	2
9	Biosimilars accessible in the market for the treatment of cancer. <i>Journal of Controlled Release</i> , 2021 , 336, 112-129	11.7	20
8	Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. <i>Drugs</i> , 2021 , 81, 1881-1896	12.1	6
7	Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?. <i>BioDrugs</i> , 2020 , 34, 723-732	7.9	4
6	Interchangeability and substitution of biosimilars: is health technology assessment (HTA) a tool for decision-making?. <i>Cadernos De Saude Publica</i> , 2019 , 35, e00087219	3.2	1
5	Current and future roles of biosimilars in oncology practice. <i>Oncology Letters</i> , 2020 , 19, 45-51	2.6	8
4	Biosimilar-to-Biosimilar Switching: What is the Rationale and Current Experience?. <i>Drugs</i> , 2021 , 81, 1859-1879	12.7	3
3	Trastuzumab in breast cancer treatment: the Era of biosimilars.. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2022 ,	2.2	

- 2 Clinical Response and Safety of Bevacizumab-awwb treatment in Patients with Metastatic Colorectal Cancer: A case series and review of the literature. ○
- 1 Biosimilars in Oncology: Latest Trends and Regulatory Status. **2022**, 14, 2721 ○